Deals and Financings
• Everest Medicines II of Shanghai, a C-Bridge company, agreed to pay up to a record $835 million in upfront and milestone payments for China rights to an Immunomedics ADC;
• Viva Biotech, a Shanghai CRO that offers partnerships to some of its clients; will seek to raise $194 million in a Hong Kong IPO that values the company at $750 million;
• Tot Biopharm, a Suzhou oncology company with a portfolio of more than ten candidates (six of them in clinical trials), filed to IPO in Hong Kong;
• Digital China Health Technologies participated in a $17.1 million extension of a Congenica Series B funding that has now raised $30 million;
• Shanghai's QTC Care, an international healthcare platform, completed a $7 million Series A funding led by Tencent to advance its AI-based treatment plans;
• Luye Pharma in-licensed China rights to PharmaMar's lurbinectedin as a treatment for small cell lung cancer, paying $5 million upfront;
• Suzhou's CStone Pharma acquired China rights to a tri-specific PD-L1 antibody developed by Zurich's Numab in returning for developing the candidate through a China Phase I trial;
IPO News
• So far, the Hong Kong Stock Exchange has IPO'd seven pre-revenue biotechs: three of them lost money in their first month. We explain why the last four have risen in value (three of them with over 65% increases).
Trials and Approvals
• I-Mab Biopharma of Shanghai began a multi-center Phase III clinical trial in Taiwan and China to evaluate its CD38 immunotherapy for multiple myeloma;
• Ascletis of Hangzhou and US-based 3-V Biosciences have started a US-China Phase II clinical trial of their partnered treatment for NASH;
• Shanghai's Sinovant Sciences was given the go-ahead to begin China registrational trials of a treatment for bile duct cancer.
Stock Symbols: (HK: 2186) (MSE: PHM) (HK: 2616) (HK: 1672)
Share this with colleagues: